CN121175056A - 核酸递送用结构物在造血系统肿瘤治疗中的使用 - Google Patents

核酸递送用结构物在造血系统肿瘤治疗中的使用

Info

Publication number
CN121175056A
CN121175056A CN202480032385.1A CN202480032385A CN121175056A CN 121175056 A CN121175056 A CN 121175056A CN 202480032385 A CN202480032385 A CN 202480032385A CN 121175056 A CN121175056 A CN 121175056A
Authority
CN
China
Prior art keywords
nucleic acid
cationic
group
treatment
hematopoietic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480032385.1A
Other languages
English (en)
Chinese (zh)
Inventor
宫本宽子
北出幸夫
赤尾幸博
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research And Development Corp Science And Technology Revitalization Organization
Original Assignee
National Research And Development Corp Science And Technology Revitalization Organization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research And Development Corp Science And Technology Revitalization Organization filed Critical National Research And Development Corp Science And Technology Revitalization Organization
Publication of CN121175056A publication Critical patent/CN121175056A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202480032385.1A 2023-05-19 2024-05-17 核酸递送用结构物在造血系统肿瘤治疗中的使用 Pending CN121175056A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023082728 2023-05-19
JP2023-082728 2023-05-19
PCT/JP2024/018410 WO2024242065A1 (ja) 2023-05-19 2024-05-17 核酸送達用構造体の造血器腫瘍の治療への使用

Publications (1)

Publication Number Publication Date
CN121175056A true CN121175056A (zh) 2025-12-19

Family

ID=93589879

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480032385.1A Pending CN121175056A (zh) 2023-05-19 2024-05-17 核酸递送用结构物在造血系统肿瘤治疗中的使用

Country Status (5)

Country Link
EP (1) EP4714453A1 (https=)
JP (1) JP7725042B2 (https=)
CN (1) CN121175056A (https=)
AU (1) AU2024276929A1 (https=)
WO (1) WO2024242065A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10487103B2 (en) 2015-03-24 2019-11-26 Gifu University Oligonucleotide derivative, oligonucleotide construct using the same, and methods for producing them
WO2017179660A1 (ja) 2016-04-14 2017-10-19 国立大学法人岐阜大学 マイクロｒｎａ－１４３誘導体
US20240238325A1 (en) 2021-04-28 2024-07-18 Japan Science And Technology Agency Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same

Also Published As

Publication number Publication date
JP7725042B2 (ja) 2025-08-19
EP4714453A1 (en) 2026-03-25
AU2024276929A1 (en) 2025-12-18
WO2024242065A1 (ja) 2024-11-28
JPWO2024242065A1 (https=) 2024-11-28

Similar Documents

Publication Publication Date Title
EP2796150B1 (en) Novel oligonucleotide conjugates and use thereof
EP2801615B1 (en) High-efficiency nanoparticle-type double-helical oligo-rna structure and method for preparing same
JP2023518970A (ja) 安定性の向上を有する修飾オリゴヌクレオチドの合成
SG185295A1 (en) Lipid-modified double-stranded rna having potent rna interference effect
CN113164507A (zh) 由多个寡核苷酸构成的通过与靶标的互补相互作用调控基因表达的多靶向核酸构建体
CN105899663B (zh) 用于基因表达控制的人工模拟miRNA及其用途
KR20210091180A (ko) 디스트로핀 엑손 스키핑을 위한 이중특이적 안티센스 올리고뉴클레오타이드
EP3858846A1 (en) Nucleic acid nanocarrier medicament, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP4331617A1 (en) Artificial nucleic acid and nucleic acid delivering method using same
JP6492014B2 (ja) 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
CN110960683B (zh) 含甲氨蝶呤的药物、其制备方法、药物组合物及其应用
CN111096965B (zh) 含双氢青蒿素的药物、其制备方法、药物组合物及其应用
JP7725042B2 (ja) 造血器腫瘍治療用組成物、造血器腫瘍治療用医薬、及び造血器腫瘍における癌化細胞の増殖抑制用組成物
CN111150852B (zh) 含顺铂的药物、其制备方法、药物组合物及其应用
EP3926047A1 (en) Nucleic acid nano-carrier drug, preparation method therefor, and pharmaceutical composition and application thereof
CN110960530B (zh) 含他克林的药物、其制备方法、药物组合物及其应用
CN110960534B (zh) 含五氟尿嘧啶的药物、其制备方法、药物组合物及其应用
CN111053913B (zh) 含阿糖胞苷的药物、其制备方法、药物组合物及应用
CN117295528A (zh) 人工核酸以及使用该人工核酸的核酸递送方法
CN110960691B (zh) 含吉西他滨的药物、其制备方法、药物组合物及应用
CN110960684B (zh) 含10-羟基喜树碱的药物、其制备方法、药物组合物及其应用
CN110960689B (zh) 含柔红霉素的药物、其制备方法、药物组合物及其应用
CN110960536B (zh) 含阿司匹林的药物、其制备方法、药物组合物及应用
CN111053919B (zh) 含伊达比星的药物、其制备方法、药物组合物及其应用
CN111068065B (zh) 含奥沙利铂的药物、其制备方法、药物组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication